Thank you, for you update Mike. call. joining Good today's afternoon. Thank
are For delighted I'm to during improve first strong of commitment those family, bolder our and for in welcome, strategic bigger who recent the creating we thanks patients' already part and quarter to to of you have we long-term as and while lives momentum new that of shareholder the substantial experienced vision support you weeks, PAVmed, to our for those to long-term execute our for strengthen plan value. success. report seek and foundation your and
runway, our always, EsoGuard groundbreaking while focus partnership to continue efforts sheet our areas, Board, strengthening management extending We our key taken commercialization, cash and balance public several opportunities Lucid and driving solidifying innovations. our on as new in exploring
with the Let me our efforts company. foundation of successful to reinforce start our
we We receive our Blackstone. anchored Vanguard Series will of by and $XX long-term later, their by We As proceeds Day, of long-term strategic generated our institutional and We've a pleased of be that Fidelity, continue offering leading gross describe, exercise approximately public including million were heavily offering including Valentine's was validation plan. $XX approximately approximately strong We from over and substantially underwritten common straight the very to fundamental strengthened position proceeds. a additional raised maybe, and those B received Dennis financial bit gross funds, million Cantor this participation cash our recent the to first consider A have meaningful led warrants. quarter. in oversubscribed months. during offerings Fitzgerald the of million stock detail more Christmas $XX between
view of sheet. of million European to the runway in strengthen $XX ended the As price financing further convertible avoided substantially debt. with in cash million warrant million our We debt approximately debt approximately $XX million requirement combined We our current account the PAVmed's exercise extends as previously small cash its funds. fully had our for announced, burn dilution, $XX the stock into $XX have cash use started forgivable in going was taking and no capital. upon and quarter debt The approximately financings PPP proceeds retire to into not off our February to by exceeded at and quarter except in XXXX rate we conversion. balance convertible debt Lucid public own a now it the decided prospect the paying with demand and loans. held cash raising and The debt of
focus I Another discuss management to strengthen team later. and a been the will bit has of of commercial our team important Board. expansion area our
Audit to past few role PAVmed's very health PAVmed and of expertise invaluable this Dr. including Board Sokolov side, the who quality and Hospira. in a advising led on care. Boards provided has the shared joined to the and all an joined recognized with White, who on committees serving with executive important guidance Board of commercialization Debbie tens aspects executive PAVmed industry, On compliance excited entities revenue who already prominent the healthcare healthcare and an healthcare was Lucid in will established Board across UK-based and commercial Debbie and strategy Board a Jacque global for companies, Dr. billions Chair. long-term Lucid major is play nationally the is thousands weeks. welcome executives employees prominent two industry including the of I over of has the
inaugural established His test to activities Lucid for its marketing and include which our will serves all Chair. and our as critical special Lucid already Sokolov commercial centers, direct-to-consumer to compliance. of we attention as own importance require be meticulous committee telemedicine expand efforts of regulatory
business major the into Now Diagnostics. subsidiary our let's with starting now our majority-owned -- Lucid dive of details
is approximately of the diagnosis the condition predisposing form Risk chronic pre-cancer million the Unfortunately patients. at patients the esophageal is subgroup are time over and risk men cancer highest death of lethal. ubiquitous between nearly family smoking development heartburn. stage less on have than diagnostics are esophageal the patients at-risk factor, XX factors highly and Americans over in Meanwhile, in all The cancer, Lucid screened of cancer focused screening commercial this a severe of esophageal chronic its chronic technology is years. are tragedy of The for of result namely, chronic well-established. is which relationship heartburn, lack company XX% effectively society Esophageal medical which obesity of So million XX race, with cancer professional direct the guidelines. these history. white XX,XXX XX deaths other risk one is and despite a sentence in heartburn heartburn for
three was minutes diagnostics or office seek University. has esophageal technologies be cancer is to products a partner, is cells from Our Case sedation. and largest payments to steaming; market little license non-invasively companies XX in Pioneer early molecular which opportunity of and the the diagnostic and Lucid and medical EsoGuard CMS less several available than EsoCheck capable the on a would a more position fortunate an secured recommended esophageal heartburn technologies lead than and as to renowned academic let pure available X% EsoGuard on California. using diagnostics; which who to screening at over in relevant approximately performed chronic these samples million led any an more breakthrough performed cancer test and million world-class research with to is anesthesia internationally can for The EsoGuard. esophageal for A screening nurse work $XX EsoGuard annual by for our esophageal mere A Dr. collected have we Irvine esophageal the an an in the of is gastroenterology translates device. in vitro performed similar early Lucid the into and detail of X% massive invested cancer -- laboratory as test society. certified laboratory from serving is for commercially cofounded capital, and penetration cancer through billion Gutierrez, patients of advisors the into only to test addressable a patients. effective Exact a Alberto cancer without in first and CLIA tool products Nick detection world journey Stan Sciences a revenue. less located among this laboratory With FDA-cleared developed device FDA prevent sampling is by and five in chronic payment a created already EsoCheck Latinas designation. our $XX market procedure patients. through commercially these to test FDA specialist with and diagnostic detection office prevent along Lucid years widespread colon also including year desk heartburn Reserve of CMS author advanced the In in diagnostic pre-cancer Western pre-cancer projects EsoGuard who commercial
on to Lucid's extraordinary raise and present well quarterly intend to to Lucid diagnostics potential value. our drive inclusion announced favorable. unlock EsoGuard medical and The strategy. growth its public fulfill is own is During evidence capital a guidelines. stand-alone We as Lucid growth seek clinical company, clinical focused commercialization, and call, as This take last expanding we support base goal the to have markets that conditions remain to future assuming as its own its long-term strategy I
contributed controlling numerous BAC targeting Life test. a one SEC public Lucid that PAVmed on and arising SPAC that effort companies. Cantor retain Of best as ultimately to by greater its the Cantor have statement us be interest of going which majority IPO PAVmed SPAC also dilution this and course, Lucid's terms and SaaS We process Lucid with us taking determined Several not from IPO public shareholders. factors served of both the Sciences engage decision SPAC accounting. discussions under a we engaged ran parallel, pursued the best an in Fitzgerald would shareholders had in firmly right would be and including and Board will the interest assist believe the from uncertainty the interest SPAC. recent Lucid. this in to through in In
EsoGuard’s occur in encouraged calls the to healthcare With update our future. appear very workers training nearly of to past. EsoGuard so in facility quarter. now thing a limitations all EsoGuard vaccinated, to first these with tests of the and the moving first access and far quarter we as pandemic-related the half has regional procedural processed testing commercial local in commercialization. support XX even we on outbreaks stand for me ease. the facilities if restrictions We're second accelerated anticipate and Lucid in XX now be the unfettered pandemic-related care activities you sales Let health forward where that
the We're including experienced sector four commercialization, experience We have Lucid XXX leaders deep roles. the and fortunate expanded industry have significantly is has very on at clinicians EsoCheck with team commercial -- full-time team. shelf also EsoGuard EsoGuard its the significantly in kits trained and help on drive to devices leadership senior as veterans previously Lucid have to these announced approximately accounts. specimen highly
and expansion sales Medtronic include previously oversees For two hired example, Barrett's our accounts, on opening sales while sales personnel other decade clinical He territory a Lucid spent and new freeing of groups team will to full-time full-time physicians. Medical. representatives up Director who of the and He existing accounts. at specialists Care growing has lead at more. on managers, of now to currently one team GI also calling recruiting train the two on over sales independent space upcoming Sales support These is new will Primary call actively focus gastroenterology and the on and We've Lucid specialists are specialists of clinicians in what regional gastroenterologists. managers both other
access tests. revenue. Our and track and diagnostic in has over experience insurance detection new of access its which leader Vice of for he as XX the secured at Cologuard an market Director a President a years and reimbursement reimbursement served had proven He record and success of as coating, cancer Care test. period has area complex reimbursement important and Reimbursement He payment for coverage of of driving Sciences market Managed during early Senior seeking Exact
Diagnostics. widely and accounts to diagnosis are held sales upper tool endoscopic utilized of CDX new both Our GI training manager, precancer. esophageal strategic enhance from the manager markets CDX
deep the they such, in both of gastroenterologists have with As esophageal community very connections disease. who specialize
few words Let's a -- spend on minutes reimbursement. few a
started to the effective January in last payment pleased in of out-of-network CMS fourth This previously We CMS -- private an EsoGuard, EsoGuard receive insurance began payment payments. that pleased -- year, noted have first later are to claims submit quarter X. we've became $X,XXX. CMS attractive the granted and we to As are determination
prolonged can is test, early during until especially remember this that it's claims secure. the to the has cycle been any coverage of contractual be encouraging, Although new commercialization important
coverage awaiting We are still local CMS determination.
a them we in pushing AdvaMed GBA. backlog trade May, Diagnostic association we of last the coverage As private Meanwhile, many the do we final Group Molecular has you administrations to of and the on determination know, from the full steam which payer persist, submitted that of of significant and We from soon. change Administrative local of resulted Medicare our our Contractor, our understand consultants Multix, pandemic ahead are to reviews but hope context coverage hear side. Palmetto
Our assemble new VP and contracts working with private is the coverage. with two to for package, Access consulting data Market firms payers Reimbursement of and payments EsoGuard securing support to
Our be directors in first with major medical advisory meeting Orlando. the will of Board Friday this held insurers
During last a major Phoenix, EsoGuard simultaneously targeting I and new internally long-term for sales EsoGuard's which our by commercialization. believe done multiple we Lucid, quarterly cans. initiative This program, commercialization which call, the announced represents supercharge project have future I seeks to of marketing
by efforts I what So that? date sales mean Our do gastroenterologists. to targeted have
patients of patients. here the traction follow-up and long-term patients because helps seeing their the and procedures. periodic become practice EsoGuard lead we'll Most are diseases of We gastroenterologists for will expand funnel esophageal new these good
continue primary in a as noted, not way others reason the experience expand I our heartburn new majority specialty. we consumers the gastroenterologist. are This teams as in space include We that detection EsoGuard we the however that already any vast that is shift fulfilling It to from have care ultimately and exact the the will a expanding The EsoGuard well. marketing efforts sales our cancer at gastroenterologists They anchor chronic requires initiative see remain market potential and away and clear physicians of of patients never our is to from early to gastroenterologists. Lucid. represent aggressively does
detect physicians To need to accommodate chronic relationship and as still cancer, well and and between as educated care of office consumers endoscopy availability space alternative consumer, referrals Lucid to EsoGuard we access on to be our be marketing As to esophageal primary our who or primary to the from esophageal the consumers, noninvasive testing. importantly, on most create new assure heartburn need testing is precancer. care a EsoGuard to east our any to coverage to centers of clinically can appropriate. outreach which patients own physician testing us educational expanded responds that requires has That for referred test physicians
has fundamentally over made Phase establishment have is details of self the in There honing accommodate X program. and and centers of Phase significant operationalizing telemedicine of Phoenix, We to work creation personnel direct-to-consumer progress are hired metropolitan two the program office of is past a been the from Lucid the We've months. the X launch completed. marketing. program space can the medical the leased couple this the clinical Preparatory that in and phases referrals area. Lucid on three pilot it program to test centers test Arizona the X this Phase
testing and Board's member We step which be being only remaining the mentioned expect committee, referral new quality to the in accept Board is infrastructure the our This to to infrastructure. for regulatory as compliance EsoGuard Dr. The necessary and weeks. physicians ready compliance centers the by I finalize coming overseen is new
leads. in established has Sokolov
summer. this Associate pilot as directors, health mentioned he’s outside our who program high-power Phoenix council; specialized with previously served commence I includes the who adviser compliance matter diagnostics sure based X care DC the Alberto as pay will attention Counsel to Jeffrey requires. and is General later Lucid colleague outside branch Gibbs to Enforcement. in-vitro and this compliance we FDA; team for management addition Gutierrez FDA committee program this of former counsel; led making and In meticulous attorney that that regulatory in Phase This general
sent gross is program each the are also stage notified final its clinical notified the summary margins projected May transitions EsoCheck quality studies marginal EsoCheck test approval The new current XXth. the regulatory the this on on quite mid-quality management and cost The completed the economics respond final telemedicine our supplies notified by office with XX are EsoGuard its diagnostics, process extensive Mark EsoGuard only therefore, center. telemedicine We, classified the given of EU's a and personnel attractive. The direct-to-consumer to We for diagnostic practitioners for can of self-referrals who of appropriate team will finalizing our with long-term company from companies. in patients these the gastroenterologists that positive experience are of vitro refer of MDR reasonable programs per telemedicine relative which regime diagnostic company We The for both comments management EU EU IVDD the who the arrangements general stream clearance, centers submitted. perform contractual the a telemedicine tests. back manufacturing. The body. handling EU-based assessment review detailed if the for under and test expect intake and types to regulatory with our Earlier in under pharmaceutical who medical the the vitro of complete nurse telemedicine in marketing efforts. marketing patients will MDD center of the potential be us indicated. physician refer space before EsoGuard ongoing the program induce to A and the will regime and was Lucid the to report up recently of perform is specifically will direct-to-consumer two clinically their The regulatory audit testing soon. each very be now those CE test to a our and More require European receive fixed as to of few been and evaluation. receive and EsoCheck marginal and our prescribing passed results test will telemedicine one then revenue further for very year, day. estimate body self-certification, therefore, technical had system, Lucid small system are regime procedures trial cost to that the result
subject studies BE-X, ESOGUARD and for in protocol which an meeting we're IVD U.S. indications this samples we These during, in collected of the study; BE-X, a terms the screening studies the patients PMA international multicenter registration FDA clinical received a using of initiatives. actively were on and presubmission enrolling a two are for EsoGuard control clinical on -- feedback support application case use. studies study to ESOGUARD of positive We our proposed
European expect patients We summer. sites enrolling begin this to
study complete application the in expect XXXX. and the enrollment submit We to PMA
FDA EsoGuard entitles the which breakthrough mentioned, close EsoCheck received and and designation I communications us FDA As device other benefits. to
We begin this pursuant discussions device have to to designation. contacted FDA breakthrough
COVID, study an clinical on future These in will for currently in that's plenty open seek screening meetings are expect powered Barrett's backlogged indication for finalize to the extending time We agency's due ESOGUARDBEX them to guidelines. support study up beyond. protocols us of Esophagus but dysplastic in to an and XXXX inclusion to we for to sufficiently input the enrollment expanded the extension in of FDA detect expanded
process we're one manufacturing the high-volume San international, working complete expect coastline we a increase this XXXX. side, the that's production manufacturer And in EsoCheck capacity manufacturing Diego end up to to EsoCheck million with year. in On by per manufacturing to units Mexico. to will This of facilities based transfer to
with that parts, devices. serving than I has separately statement on on samples pre-cancer cells, spend up come and available EsoCheck. screening cleaning really analysis. deaths to to This cancer much only that and have less that, relates Lucid. available no is data collection as with EsoGuard detection other competitive first of heartburn commercially prevent tests capable other are tool, stated to products, biomarker widespread These preliminary EsoCheck few like heartburn esophageal cancer to a through with few of esophageal collected the other chronic in to abstracts for EsoGuard topics on biomarkers cell purport performed a our the sufficient as in and Finally, frequently publications There are a I'd early commercially widespread EsoGuard investors as to some diagnostic, to and esophageal and and been worthy and minutes before of the it on for landscape a cancer, test accuracy discussions biomarkers pre-cancer chronic and There one moving patients. with serve our other two patients.
which One has being of our set Exact developed of -- Sciences. by a these Mayo relationship are, with Clinic being developed biomarkers biomarkers
cells devices the of its dilution the a Medtronic They string struggle from molecular can key device sample device in a from no up the in retrieval. of perform use. believe, to changes medicine. sensitivity, contamination stomach accuracy, changes compared as XX% few power pre-cancer include cells. esophageal greater the was to during data early data Picking funded these ago, proper becoming biomarkers falls part Haystack. believe of is with We are as Needle being the disease cap protecting sample molecules. EsoGuard's replicate in to the occur while validation the of These as sponge to demonstrated see the ultimate biomarker the the is in lack in markets States our of the short pad X% and which longer aware and well-designed case-control Proverbial XXX as device Western will which the a sets. cloned not and in published the direct feature these Cytosponge investigators patent-protected All sampling do a anytime The the to We variation as Mayo Brillo Consortium to distal is over EsoCheck. consultants These Dr. the foreseeable I sample EsoGuard three well which the EsoCheck disease on on years all -- mouth. That these biomarkers as cells targeted and including, sample We the other today samples. data insofar Case Any Faculty terms Shahin outside EsoCheck, entry, the have and however, including region on barrier anatomically are same performed EsoGuard translational Mayo sample NCI on that DNA a data performance investigators. esophagus, The by training physician future. United swamped ability specificity differentiating Mayo of presented competition of is indiscriminately of science markers patient to in study than some Esophageal
into attention biopsy of tests esophageal test, very amounts a flowing with complex fundamental but These which my in liquid any minute of state blood. biopsy capital rates asked obviously arise cancers. Stage over that does is tumor opinion. get Stage biopsy and the XX% cancer about is Finally, poor mortality DNA companies from early-stage the This prognosis cancer EsoGuard blood. we not reason The topic of the X that and looking can potential to in X This liquid is the intense cancerous briefly means esophageal me prevent is liquid serious pre-cancer pre-cancer way detect questions in detect threat in Barrett's from detect threat Esophagus. let frequently mutations only no such don't invade cells that the cancer and have to to death These early as blood vessels. face
So from their esophageal the to indistinguishable actual DNA. is the essentially only way up collect these to so even DNA bloodstream cells. that in would detect be The in early unlikely ended normal event changes
close other products. So some our I'll across with now updates brief
I filings As are refer we to have PAVmed, of with for encourage those me information last questions. background would us you time with our winning to SEC call, just you don't any and who for our much context to for contact additional provide website or and
a on panel surgeons lower with a in ago. couple treat an Let's the Calvin [indiscernible] been This Calvin the contacts carpal orthopedic starts CarpX, invasive he of brings in Trice fat invasive has Trice, launch role volume advisory us includes full-time space tasked manager, start sales. ago. in filed carpal commercialization distributions. at since deliberate a minimally with Calvin hand several committed decade the to Calvin commercialization of and an At corporate and experience brings efforts procedural it excited tunnel accelerate case reorganizing a our the steady important years procedural welcome acquired look played commercialization successful tunnel including to which to and device, release I'm has and extended which national broaden surgery the to and Medical. our plan safety, CarpX Roberts initial focused our year. a over months steps who this with new remain syndrome. sales to first We today. device of optimizing later minimally
report body the to their CE XX. we recently has EsoCheck new notified current the us but receive that CarpX Our the MDR CarpX EU-based final regime with May the on regulatory of We under transition submission also to technical notified MDD approval expect as been review summary confirmation, the await completed. Mark regime before file
radically I'm set. day will to made the and NextFlo. slide, transform with the of the million we very Once Next it our set, cost in NextFlo infusion Infusion each States. by effectiveness United infusions excited progress the commercialized efficiency administered have IV seek
Our work pumps in infusions. to-date clearly set these to has able NextFlo flow believe replaced actually demonstrates and XX% electronic that constant is We provide approaching IV pumps. accuracy works future with and it the of over
We are in to of testing begin validation final testing the midst design verification freeze soon. and verification expect
end We half the year clearance FDA targeting with the first are XXX(k) submission in of by the XXXX. of
pumps. license technology specifically for discussions We infusion the diligence continue to partner to engage in and to technologic disposable support with a strategic large NextFlo
to however, application we'll self-commercialize the this be technology continue, this for we well for [indiscernible]. positioned application continue discussions advance those to As and
America is Our steps is is PortIO The PortIO and commence. awaiting implantable, intraosseous study vascular currently abroad. in in South access regulatory the device US to ready Colombia
open IRB and In four processes meeting the hope soon meetings anticipation they begin patients FDA approval reopening awaiting studies approval we're we but slowed protocol X-week meantime, IVD pre-submission delays is implant based and was that is are process once these severe South set the pre-submission study the to centers meeting scheduled have once we're facing well. US a summer. We and however up. by duration. which initiated in IRB studies strengthen We US, to to non-COVID COVID The performing of in enrolling the enrollment ready so get going of to in to our animal expect similar America, our for secured. on are get long-term an discuss the medical this final preclinical data outbreak PortIO
balloon emerging a progressing first portfolio, who well. of We is Dr. few thermal after NYU. animals catheter technology. is the included study, believe a animal XXXX. products successful pending, Caldus on secured for which were of completed successful recently of our channel standard Next through we're on work innovations adjacent working of procedure. was ablation the clearance and schedule We but using device endoscope ablation esophageal proprietary survived our lining esophageal submission the Histopathology Poppers with from This demonstrated in direct highlights a FDA our study in David we
call, non-invasive our in was and advancing partly Work developed during third-party animal fact the to tubes. ready recently testing Canon technology. pediatric the agreement work which license XXXX. going had testing submission next prototype terminated in our development on XXX(k) space, our a expecting is USA in this targeting our volunteers glucose superior. model advanced quarter resorbable later based diabetic and own animal we previewed is late still research, We're with to And in own last technology a and continue Diagnostics ear partner as this This human manufacturing to We proprietary develop DisappEAR and for subsidiary FDA initiate this we our closely our expect believe to and well be we monitor on year. that technology Solys
long-term with Lucid this a my PAVmed activity for a Lucid is since PAVmed few close I'd comes immediate up does In discussions investors follows: and actually Again of portion is assuming question. as to is term, comments our and the get stand-alone the a frequently public topic represents Finally, vision in like post what such straightforward PAVmed's Lucid? become I on question with significant this a direct pretty company. frequently value,
if to we We equity PAVmed have a retains that Lucid only interest. public, controlling will clear made take proceed majority it
But an a revenue benefit continue As to long-term. deeper growth. consolidated Lucid for financials but we'll Lucid and revenue will strategy, and our access medium role to report Lucid itself successes. will have from continue its the vision play to growth over recognize capital will question important there's about drive and PAVmed and directly PAVmed to such PAVmed
of device, PAVmed me value thing. be let and engine as So one future is the at past Lucid a design expanded and for clear access, integrated be deep greatly and disciplines, PAVmed a across to is Lucid. infrastructure manufacturing, not fruits clinical been years an rapidly This about of CLIA infrastructure in trials The more molecular skill to with company potentially laboratory and and diagnostics. commercialization, PAVmed value best-in-class The and one tightly market set of which has powerful broadly. serve broad the team building medical process and technical network in both regulatory with three of built To the expertise over experience diagnostics success development, that and even has infrastructure innovation consultants. the contrary, across expertise a consists our experts building device all holding
portfolio such vision is consists. CarpX our simple our of form with also from value infusion and as be for quite from succeed suite and we can the already PAVmed be did engine in of Lucid. products, it So acquire can as generate we This technologies license groundbreaking this our in is future or technologies
promising creating our that Western on Case as to update Lucid on three We With the centers pounce our them an increased value just with just very financials. innovators with consider of success assess in it greatly exciting on us the provide has not for to but number to each pass are partnering partners technologies. on with of but Our won't most shareholders, very Dennis our Lucid to for carefully, academic we we did and of we I'll years ago. hesitate opportunities these soliciting
